Response rates were much lower than in RA patients treated with adalimumab in the same clinical study, suggesting that TNF-α blockade has a prevalent role in the improvement of signs and symptoms of RA over LT-α blockade (74). The gene discussed is LTA; the disease is rheumatoid arthritis.